AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23281382
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of lamivudine (LAM) and adefovir dipivoxyl (ADV)
Trial: 20179232
Drug: Hydrogen sulfate
RxNorm normalized name: XYLAN, HYDROGEN SULFATE
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen sulfate (Hyd-Sulfate) capsule of AZD6244 (75 mg twice daily)
Trial: 20179232
Drug: Hydrogen sulfate
RxNorm normalized name: XYLAN, HYDROGEN SULFATE
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen sulfate (Hyd-Sulfate) capsule
Trial: 17268205
Drug: Biventricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular therapy (biventricular therapy + defibrillator)
Trial: 17268205
Drug: Biventricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular therapy
Trial: 12113615
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.06 mg kg(‐1) followed 2 min later by rocuronium 0.54 mg kg(‐1)
Trial: 12113615
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of 0.10 mg kg(‐1) followed 2 min later by rocuronium 0.50 mg kg(‐1)
Trial: 12113615
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of rocuronium 0.06 mg kg(‐1) followed 3 min later by administration 0.54 mg kg(‐1)
Trial: 12113615
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of 0.10 mg kg(‐1) followed 3 min later by injection of 0.50 mg kg(‐1)
Trial: 12113615
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection followed 3 min later by rocuronium 0.60 mg kg(‐1)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (200 mg saquinavir and 300 mg ritonavir)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (200 mg saquinavir and 600 mg ritonavir)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (400 mg saquinavir and 300 mg ritonavir)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (400 mg saquinavir and 600 mg ritonavir)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (600 mg saquinavir and 200 mg ritonavir)
Trial: 9585800
Drug: Ritonavir plus
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir plus saquinavir (600 mg saquinavir and 600 mg ritonavir)
Trial: 2146885
Drug: Urodilatin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urodilatin (all doses)
Trial: 404621
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin infusion (0.1 units/kg/hour)
Trial: 24492859
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (IST) for malaria using artemether-lumefantrine (AL) with a six dose regimen.
Trial: 24492859
Drug: Intermittent screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening and treatment (IST) for malaria.
Trial: 17589421
Drug: morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine + morphine (MM)
Trial: 17589421
Drug: morphine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine + remifentanil (MR)
Trial: 10025899
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with alkylating agents
Trial: 10025899
Drug: Hydroxyurea and
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea and other non-alkylating agents
Trial: 7740509
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Ardeparin) administered subcutaneously
Trial: 7740509
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) administered subcutaneously
Trial: 7740509
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Ardeparin) administered intravenously
Trial: 7740509
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) administered intravenously
Trial: 7740509
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Ardeparin)
Trial: 7042603
Drug: Rifampin 450
RxNorm normalized name: rifampin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 450 mg daily (Regimen A)
Trial: 7042603
Drug: Rifampin 1200
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 1200 mg once a month (Regimen B)
Trial: 31597662
Drug: ME-344 10
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-344 10 mg/kg intravenous on days 8, 15, and 21
Trial: 28887117
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment (14∼16 J/cm2)
Trial: 28887117
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (0 J/cm2)
Trial: 21159325
Drug: Self-reported motivation
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-reported motivation measures (Change Questionnaire & Client Motivational for Therapy Scale)
Trial: 10561948
Drug: Prenolol 50
RxNorm normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenolol 50 mg
Trial: 10561948
Drug: Prenolol 100
RxNorm normalized name: alprenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenolol 100 mg
Trial: 1747577
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg plus slow release nifedipine 20 mg twice daily
Trial: 6621623
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 3500 IU of heparin subcutaneously every eight hours (Group 1)
Trial: 6621623
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose of heparin to maintain activated partial thromboplastin time between 31.5 and 36 seconds (Group 2)
Trial: 31443692
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (RIC) at 200 mmHg, twice daily for 6 months
Trial: 31443692
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group at 60 mmHg, twice daily for 6 months
Trial: 28592257
Drug: Maxacalcitol ointment
RxNorm normalized name: Paricalcitol
DrugBank: Maxacalcitol (DB06272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol ointment applied twice a day for 8 weeks
Trial: 18541125
Drug: Maxacalcitol ointment
RxNorm normalized name: Paricalcitol
DrugBank: Maxacalcitol (DB06272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol ointment
Trial: 25683077
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 25% dextrose orally just before laser therapy
Trial: 25683077
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with paracaine eye drops
Trial: 18639659
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue spray and collagen patch applied to the axillary fossa
Trial: 26996929
Drug: Drug-treated hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-treated hypertension
Trial: 11791023
Drug: Drug-treated hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-treated hypertension with target blood pressure below 130/85
Trial: 8610239
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 on day 1 (Group A)
Trial: 8610239
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8 (Group B)
Trial: 8610239
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 on days 1 and 15 and 12.5 mg/m2 on day 8 (Group C)
Trial: 1934538
Drug: Ketanserin 10
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 10 mg twice daily
Trial: 1981022
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg twice daily
Trial: 1934538
Drug: Ketanserin 5
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 5 mg twice daily
Trial: 6304907
Drug: Veralipride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralipride (100 mg per day for 20 days)
Trial: 6304907
Drug: Natural estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural estrogens (1.25 mg for 20 days)
Trial: 30760299
Drug: Internet-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based guided self-help (GSH) treatment comprising eight sessions followed by three booster sessions
Trial: 30760299
Drug: Placebo-inspired waitlist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-inspired waitlist control group receiving weekly messages with positive expectations
Trial: 30760299
Drug: Pure waitlist
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure waitlist control group receiving weekly messages asking to fill in a questionnaire
Trial: 27487357
Drug: Pharmacist-led, home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led, home-based medication management intervention delivered within 7 days after hospital discharge
Trial: 27487357
Drug: Pharmacist-led, home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led, home-based medication management intervention
Trial: 24836205
Drug: Ataluren (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren (10 mg/kg in morning, 10 mg/kg midday, and 20 mg/kg in evening)
Trial: 24836205
Drug: Ataluren (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren (in subgroup not using chronic inhaled tobramycin)
Trial: 24836205
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in subgroup not using chronic inhaled tobramycin)
Trial: 22854665
Drug: TLR9 agonist
RxNorm normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR9 agonist (CPG 7909) with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Trial: 22854665
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with pneumococcal conjugate vaccine (Prevnar, Pfizer)
Trial: 20795842
Drug: Atenolol therapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol therapy (100 mg/day for 5 weeks)
Trial: 17040921
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor immunohistochemistry analysis in Huntington's disease cases
Trial: 17040921
Drug: GABA(A) receptor
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA(A) receptor immunohistochemistry analysis in control cases
Trial: 17560868
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg plus drospirenone 2 mg
Trial: 15090932
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (50 mg)
Trial: 15090932
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (100 mg)
Trial: 15090932
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (200 mg)
Trial: 15090932
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (400 mg)
Trial: 14517707
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (all doses)
Trial: 1558774
Drug: Continuous cotrimoxazole
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous cotrimoxazole administration
Trial: 1558774
Drug: Intermittent cotrimoxazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent cotrimoxazole administration (3 days a week)
Trial: 29602225
Drug: Oral microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiota in children developing allergic disease (asthma)
Trial: 29602225
Drug: Oral microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiota in healthy children
Trial: 29602225
Drug: Lactobacillus gasseri
RxNorm normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus gasseri and L. crispatus in healthy children
Trial: 16298069
Drug: Probable medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probable medication overuse headache (pMOH)
Trial: 11964279
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg alternate-day oral prednisone
Trial: 11964279
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg alternate-day oral prednisone
Trial: 9856375
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard (NPA) 10 or 20 mg twice a day
Trial: 9856375
Drug: Nifedipine gastrointestinal
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine gastrointestinal therapeutic system (NGITS) 30 or 60 mg once a day
Trial: 9856375
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 or 10 mg once a day
Trial: 7654468
Drug: Estrogen and
RxNorm normalized name: Conjugated estrogen and norgestrel only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen and 1000 mg of supplemental calcium each day
Trial: 2762589
Drug: Betamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (1 x 8 mg) and dixyrazine (4 x 10 mg)
Trial: 2762589
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide (4 x 1 mg/kg)
Trial: 2762589
Drug: Betamethasone-dixyrazine and
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone-dixyrazine and high-dose metoclopramide
Trial: 976301
Drug: Isoproterenol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (beta-adrenergic receptor stimulatory agent)
Trial: 976301
Drug: Propranolol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (beta-adrenergic receptor blocking agent)
Trial: 31995619
Drug: Pembrolizumab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab combination therapy
Trial: 25124565
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK cell therapy
Trial: 21812536
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of CpG 7909 (1.05 mg/kg)
Trial: 21812536
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose of CpG 7909 (0.45 mg/kg)
Trial: 21812536
Drug: Multiple weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multiple weekly subcutaneous doses of CpG 7909 (0.45 mg/kg)
Trial: 21812536
Drug: CpG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG 7909 administration
Trial: 19294955
Drug: Ramelteon, 8
RxNorm normalized name: Ramelteon, 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon, 8 mg nightly for 6 months
Trial: 17465861
Drug: Lidocaine (needle-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (needle-free injection)
Trial: 14727250
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and IMRT with subcutaneous amifostine (Ethyol, WR-2721)
Trial: 1901076
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rtPA) 100 mg
Trial: 31348731
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of MenAC-TT vaccine
Trial: 31348731
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of MenAC-TT vaccine
Trial: 31348731
Drug: Both 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 1 and 2 doses of MenAC-TT vaccine
Trial: 28667881
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Trial: 19190912
Drug: Urokinase instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase instillation (thrice daily)
Trial: 17552960
Drug: Sildenafil (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25, 50 or 100 mg)
Trial: 17552960
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 or 20 mg)
Trial: 16109114
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 mg/day) for 6 weeks
Trial: 9536583
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler and Accuhaler
Trial: 7971707
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of felodipine
Trial: 22863216
Drug: IL18 rs360719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL18 rs360719 CC genotype
Trial: 22863216
Drug: IL18 rs360719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GG
Trial: 22863216
Drug: IL18 rs360719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GA
Trial: 22863216
Drug: IL18 rs360719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL18 rs360719 CC combined with IL12A rs568408 GG/AA
Trial: 22863216
Drug: IL12B rs3212227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL12B rs3212227 AA combined with IL18 rs360719 CC
Trial: 22863216
Drug: rs3212227 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs3212227 CC and rs360719 TC genotypes
Trial: 14681845
Drug: Stevioside (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stevioside (1 g)
Trial: 14681845
Drug: Maize starch
RxNorm normalized name: Maize starch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize starch (1 g)
Trial: 11642632
Drug: DTaP‐HB with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐HB with licensed IPV (IPOL) administered separately
Trial: 11642632
Drug: Separate doses
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate doses of OPV, DTaP, and HB
Trial: 8311205
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine infusion at 7 ml.h‐1 of a 0.25% solution
Trial: 8311205
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine infusion at 25 ml.h‐1 of a 0.07% solution
Trial: 343727
Drug: naproxen (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500-750 mg daily)
Trial: 343727
Drug: phenylbutazone (400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylbutazone (400-600 mg daily)